Multiple sclerosis (MS) is an autoimmune demyelinating and neurodegenerative disease of
the central nervous system, and the leading cause of nontraumatic neurological disability in …

In the majority of patients multiple sclerosis starts with a relapsing remitting course (RRMS),
which may at later times transform into secondary progressive disease (SPMS). In a minority …

Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …

One of the most frequent statements, provided in different variations in the introduction of
experimental studies on multiple sclerosis (MS), is that “Multiple sclerosis is a demyelinating …

Objective: To investigate the safety and efficacy of rituximab in multiple sclerosis (MS).
Methods: In this retrospective uncontrolled observational multicenter study, off-label …

Monoclonal antibodies that target CD20 expressing B cells represent an important new
treatment option for patients with multiple sclerosis (MS). B‐cell‐depleting therapy is highly …

Multiple sclerosis (MS) and neuromyelitis optica (NMO) are autoimmune demyelinating
diseases of the central nervous system (CNS), having distinct immunological and …

Background: Ublituximab, a novel monoclonal antibody (mAb) targeting a unique epitope on
the CD20 antigen, is glycoengineered for enhanced B-cell targeting through antibody …

Interest in CD8+ T cells and B cells was initially inspired by observations in multiple
sclerosis rather than in animal models: CD8+ T cells predominate in multiple sclerosis …

Importance Comparative real-world effectiveness studies of initial disease-modifying
treatment (DMT) choices for relapsing-remitting multiple sclerosis (RRMS) that include …